Loading stock data…
CRNX
$39.02+0.24 (+0.62%)
Market ClosedLast close May 1
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crinetics Pharmaceuticals, Inc. in the Healthcare sector is trading at $39.02. The stock is currently 33% below its 52-week high of $57.99, remaining 4.1% below its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why CRNX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$39.02
Potential Upside
5%
Whystock Fair Value$40.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$83.36+113.6%
Range$55.00 – $97.00
Fundamentals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.28%
Volume
Today's trading volume
1.06M
Recent News
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks 6th on this list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) first appeared in the 13F portfolio of Farallon Capital in the third quarter of 2018. Back then, this position comprised over 141,000 shares. By early 2019, however, this stake […]
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best biotech stocks with highest upside potential. As of the April 24 closing, the stock carries a strongly bullish consensus sentiment. With a price target of $86.71, it yields more than 126% upside potential. It received Buy ratings from all 8 analysts who provided coverage. On […]
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.